How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story

Simply Wall St.08-18

MannKind Corporation recently reported past second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier, but shifting from a small profit to a net loss ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660431109?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-18 01:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660431109","market":"hk","top_or_hot":-1,"title":"How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story","media":"Simply Wall St.","content":"<div>\n<p>MannKind Corporation recently reported past second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier, but shifting from a small profit to a net loss ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/how-mannkinds-mnkd-rising-revenue-but-renewed-losses-could-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 01:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/how-mannkinds-mnkd-rising-revenue-but-renewed-losses-could-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MannKind Corporation recently reported past second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier, but shifting from a small profit to a net loss ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/how-mannkinds-mnkd-rising-revenue-but-renewed-losses-could-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/how-mannkinds-mnkd-rising-revenue-but-renewed-losses-could-r","article_id":"2660431109","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/how-mannkinds-mnkd-rising-revenue-but-renewed-losses-could-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660431109","pubTimestamp":1786987509,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MannKind Corporation recently reported past second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier, but shifting from a small profit to a net loss of US$19.03 million. \nDespite higher revenue for both the quarter and first half of 2026, MannKind’s return to losses highlights the pressure its cost base is placing on profitability. \nWe’ll now examine how MannKind’s higher revenue but renewed net loss may affect the existing investment...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"MannKind (MNKD) 收入不断增长但再次亏损如何重塑其增长投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind Corporation recently reported past second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier, but shifting from a small profit to a net loss of US$19.03 million.  Despite higher revenue for both the quarter and first half of 2026, MannKind’s return to losses highlights the pressure its cost base is placing on profitability.  We’ll now examine how MannKind’s higher revenue but renewed net loss may affect the existing investment narrative around its growth plans. Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementMannKind Investment Narrative RecapTo own MannKind today, you have to believe its Technosphere inhaled platform and diabetes and lung disease focus can eventually support sustainable profits despite ongoing losses. The latest Q2 2026 results, with revenue up to US$109.37 million but a US$19.03 million net loss, reinforce that the near term catalyst remains execution on Afrezza and rare lung programs, while the biggest risk is a cost base that keeps expanding faster than revenue. On that front, this quarter’s loss is a material reminder rather than a thesis changer. Against that backdrop, the recent positive INFLO 1 data for nintedanib DPI in idiopathic pulmonary fibrosis feels particularly relevant. It ties directly into the idea that MannKind’s future may depend on broadening beyond Afrezza and Tyvaso DPI royalties. Early safety and pharmacokinetic results do not resolve today’s profitability issues, but they matter for the medium term catalyst of reducing product concentration risk if later stage INFLO 2 data support a new inhaled IPF option. Yet, while Afrezza’s pediatric opportunity looks promising, investors should also be aware of how rising R&D and commercial costs could... Read the full narrative on MannKind (it's free!)MannKind's narrative projects $554.4 million revenue and $85.4 million earnings by 2029. This requires 15.4% yearly revenue growth and a $109.3 million earnings increase from -$23.9 million today.Uncover how MannKind's forecasts yield a $7.59 fair value, a 97% upside to its current price.Exploring Other PerspectivesMNKD 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, assuming only about 7.4% annual revenue growth to roughly US$447.0 million and modestly positive earnings by 2029, so this return to losses may push you to weigh those more pessimistic views against the more optimistic catalyst of Technosphere expansion and decide which narrative now feels closer to reality.Explore 3 other fair value estimates on MannKind - why the stock might be worth just $4.50!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your MannKind research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.Seeking Other Investments?Our top stock finds are flying under the radar-for now. Get in early:AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660431109","isCrawlerRequest":true}